Adagio Medical specializes in advanced medical technologies aimed at improving patient outcomes in the field of cardiovascular health. The company focuses on developing innovative solutions for the treatment of atrial fibrillation and other related conditions. Their flagship product utilizes a unique approach to catheter-based therapies, which enhances the precision and effectiveness of cardiac procedures. This technology is designed to provide physicians with better tools for navigating complex anatomical structures, ultimately leading to improved procedural success rates and reduced recovery times for patients.

In addition to their core product offerings, Adagio Medical emphasizes the importance of scientific research and development in driving their technological advancements. The company is committed to leveraging cutting-edge materials and engineering techniques to create devices that are not only effective but also safe for patients. Their ongoing research initiatives aim to refine existing technologies and explore new avenues for treatment, ensuring that they remain at the forefront of innovation in the medical device industry. Through a combination of rigorous scientific inquiry and practical application, Adagio Medical strives to enhance the quality of care for individuals suffering from cardiovascular diseases.

United States

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLASTM Cryoablation System which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. IDE Pivotal Study.

Adagio Medical

Company Details